[Oral therapy for interstitial cystitis: pentosan polysulfate sodium]

Area of Science:

• Urology
• Pharmacology
• Ophthalmology

Background:

• Interstitial cystitis/bladder pain syndrome (IC/BPS) is linked to urothelial glycosaminoglycan layer damage.
• Pentosan polysulfate sodium (PPS) is an oral therapy aimed at repairing this damaged layer.
• This review examines PPS history, efficacy, guidelines, and potential maculopathy correlation.

Purpose of the Study:

• To review the history and efficacy of pentosan polysulfate sodium (PPS) for interstitial cystitis/bladder pain syndrome (IC/BPS).
• To evaluate the current guideline status of PPS in IC/BPS management.
• To investigate the potential association between PPS therapy and maculopathy.

Main Methods:

• Literature research was conducted using PubMed and Embase databases.

Main Results:

• PPS is approved for IC with glomerulations or Hunner lesions, with efficacy supported by randomized trials.
• It's recommended as a basic therapy for IC/BPS, requiring re-evaluation after six months.
• Potential side effects include mild hemodilution, nausea, and hair loss. A debated correlation with maculopathy led to ophthalmologic monitoring recommendations.
• Ongoing litigation in Germany has disrupted PPS availability, causing patient undersupply.

Conclusions:

• Pentosan polysulfate sodium (PPS) holds a unique position as the sole causal treatment for IC/BPS.
• Despite legal challenges and unresolved maculopathy concerns, PPS should remain a key therapeutic option for IC/BPS.
• Ensuring patient access to PPS is critical despite current trade disruptions.